Pietschmann Thomas

List of Publications by Year
in descending order

171	17,912	23567 58	13379 130
papers	citations	h-index	g-index

183	183	183	15848
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets. Digestive Diseases, 2014, 32, 525-537.	1.9	3,128
2	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	30.7	2,561
3	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7408-7413.	7.1	651
4	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine, 2011, 17, 589-595.	30.7	631
5	Antiâ€infective properties of epigallocatechinâ€3â€gallate (<scp>EGCG</scp>), a component of green tea. British Journal of Pharmacology, 2013, 168, 1059-1073.	5.4	415
6	Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses. Journal of Virology, 2006, 80, 5308-5320.	3.4	363
7	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 295-308.	16.8	345
8	Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs. Journal of Virology, 2001, 75, 1252-1264.	3.4	336
9	Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture. Journal of Virology, 2002, 76, 4008-4021.	3.4	330
10	Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions. PLoS Pathogens, 2007, 3, e103.	4.7	290
11	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 2011, 54, 1947-1955.	7.3	255
12	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14416-14421.	7.1	244
13	Novel Insights into Hepatitis C Virus Replication and Persistence. Advances in Virus Research, 2004, 63, 71-180.	2.1	243
14	Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology, 2007, 46, 1722-1731.	7.3	222
15	Interferon-Î± inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology, 2001, 82, 723-733.	2.9	210
16	Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain. Journal of Virology, 2005, 79, 3187-3194.	3.4	208
17	The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells. Journal of Virology, 2007, 81, 588-598.	3.4	201
18	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. Journal of Virology, 2010, 84, 5751-5763.	3.4	201

#	Article	IF	Citations
19	Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes. Journal of Virology, 2007, 81, 4591-4603.	3.4	198
20	High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI. Journal of Biological Chemistry, 2006, 281, 18285-18295.	3.4	186
21	Interferon-Î±â€“Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 1885-1897.e10.	1.3	177
22	Interferon lambda 4 signals via the IFNÎ» receptor to regulate antiviral activity against HCV and coronaviruses. EMBO Journal, 2013, 32, 3055-3065.	7.8	177
23	CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. Journal of General Virology, 2009, 90, 48-58.	2.9	162
24	Alternative Approaches for Efficient Inhibition of Hepatitis C Virus RNA Replication by Small Interfering RNAs. Journal of Virology, 2004, 78, 3436-3446.	3.4	158
25	Foamy Virus Capsids Require the Cognate Envelope Protein for Particle Export. Journal of Virology, 1999, 73, 2613-2621.	3.4	152
26	Virucidal Activity of World Health Organizationâ€“Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. Journal of Infectious Diseases, 2017, 215, 902-906.	4.0	151
27	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology, 2006, 43, 592-601.	7.3	150
28	Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut, 2014, 63, 1137-1149.	12.1	148
29	Targeting of Hepatitis C Virus Core Protein to Mitochondria through a Novel C-Terminal Localization Motif. Journal of Virology, 2004, 78, 7958-7968.	3.4	144
30	Structural and Functional Characterization of Nonstructural Protein 2 for Its Role in Hepatitis C Virus Assembly. Journal of Biological Chemistry, 2008, 283, 28546-28562.	3.4	135
31	Efficient trans -Encapsidation of Hepatitis C Virus RNAs into Infectious Virus-Like Particles. Journal of Virology, 2008, 82, 7034-7046.	3.4	131
32	Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology, 2007, 46, 330-338.	7.3	127
33	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research, 2018, 248, 53-62.	2.2	124
34	NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus. Journal of Biological Chemistry, 2010, 285, 31446-31461.	3.4	119
35	Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations. PLoS Pathogens, 2009, 5, e1000475.	4.7	116
36	Clinical course of infection and viral tissue tropism of hepatitis C virusâ€“like nonprimate hepaciviruses in horses. Hepatology, 2015, 61, 447-459.	7.3	116

#	Article	IF	Citations
37	A Particle-Associated Glycoprotein Signal Peptide Essential for Virus Maturation and Infectivity. Journal of Virology, 2001, 75, 5762-5771.	3.4	112
38	A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. Gastroenterology, 2012, 143, 213-222.e5.	1.3	111
39	MAP-Kinase Regulated Cytosolic Phospholipase A2 Activity Is Essential for Production of Infectious Hepatitis C Virus Particles. PLoS Pathogens, 2012, 8, e1002829.	4.7	110
40	Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors. PLoS Pathogens, 2010, 6, e1000978.	4.7	109
41	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology, 2009, 50, 1638-1645.	7.3	108
42	Hepatitis C Virus p7 is Critical for Capsid Assembly and Envelopment. PLoS Pathogens, 2013, 9, e1003355.	4.7	102
43	Efficient hepatitis C virus cell culture system: What a difference the host cell makes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9739-9740.	7.1	91
44	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. Journal of Infectious Diseases, 2011, 204, 1830-1838.	4.0	90
45	Natural reservoirs for homologs of hepatitis C virus. Emerging Microbes and Infections, 2014, 3, 1-9.	6.5	88
46	Apolipoprotein E Codetermines Tissue Tropism of Hepatitis C Virus and Is Crucial for Viral Cell-to-Cell Transmission by Contributing to a Postenvelopment Step of Assembly. Journal of Virology, 2014, 88, 1433-1446.	3.4	88
47	Low pH-dependent Hepatitis C Virus Membrane Fusion Depends on E2 Integrity, Target Lipid Composition, and Density of Virus Particles. Journal of Biological Chemistry, 2009, 284, 17657-17667.	3.4	79
48	Interferonâ€inducible cholesterolâ€25â€hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology, 2015, 62, 702-714.	7.3	78
49	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2132-2139.	3.2	75
50	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. Journal of Infectious Diseases, 2010, 201, 1859-1866.	4.0	72
51	Cell Culture Systems for Hepatitis C Virus. Current Topics in Microbiology and Immunology, 2013, 369, 17-48.	1.1	72
52	A molecular tweezer antagonizes seminal amyloids and HIV infection. ELife, 2015, 4, .	6.0	71
53	Development of novel therapies for hepatitis C. Antiviral Research, 2010, 86, 79-92.	4.1	70
54	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. Gastroenterology, 2010, 138, 1875-1884.	1.3	68

#	Article	IF	Citations
55	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. Gastroenterology, 2012, 143, 223-233.e9.	1.3	66
56	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. Hepatology, 2013, 57, 492-504.	7.3	66
57	Characterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using trans -Complementation. Journal of Virology, 2009, 83, 11682-11693.	3.4	65
58	Flunarizine prevents hepatitis C virus membrane fusion in a genotypeâ€dependent manner by targeting the potential fusion peptide within E1. Hepatology, 2016, 63, 49-62.	7.3	64
59	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. Journal of Infectious Diseases, 2013, 207, 281-287.	4.0	57
60	Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion. Viruses, 2014, 6, 1149-1187.	3.3	56
61	An Evolutionarily Conserved Positively Charged Amino Acid in the Putative Membrane-Spanning Domain of the Foamy Virus Envelope Protein Controls Fusion Activity. Journal of Virology, 2000, 74, 4474-4482.	3.4	54
62	Two pathogen reduction technologiesâ€"methylene blue plus light and shortwave ultraviolet lightâ€"effectively inactivate hepatitis C virus in blood products. Transfusion, 2013, 53, 1010-1018.	1.6	54
63	Isolate-dependent use of claudins for cell entry by hepatitis C virus. Hepatology, 2014, 59, 24-34.	7.3	54
64	Protein Interactions during the Flavivirus and Hepacivirus Life Cycle. Molecular and Cellular Proteomics, 2017, 16, S75-S91.	3.8	53
65	Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. Journal of Hepatology, 2017, 67, 480-489.	3.7	51
66	Mouse-Specific Residues of Claudin-1 Limit Hepatitis C Virus Genotype 2a Infection in a Human Hepatocyte Cell Line. Journal of Virology, 2010, 84, 964-975.	3.4	50
67	Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants within vitroresistance to SR-BI-targeting agents. Hepatology, 2014, 60, 1508-1518.	7.3	50
68	Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Reports, 2015, 12, 864-878.	6.4	50
69	Prototype Foamy Virus Envelope Glycoprotein Leader Peptide Processing Is Mediated by a Furin-Like Cellular Protease, but Cleavage Is Not Essential for Viral Infectivity. Journal of Virology, 2004, 78, 13865-13870.	3.4	49
70	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. Journal of Infectious Diseases, 2013, 208, 1943-1952.	4.0	47
71	HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. Journal of Hepatology, 2006, 45, 5-12.	3.7	46
72	Entry and replication of recombinant hepatitis C viruses in cell culture. Methods, 2013, 59, 233-248.	3.8	46

#	Article	IF	Citations
73	Mechanisms of Methods for Hepatitis C Virus Inactivation. Applied and Environmental Microbiology, 2015, 81, 1616-1621.	3.1	46
74	cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites. Cell Host and Microbe, 2016, 20, 443-457.	11.0	46
75	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB. PLoS Pathogens, 2018, 14, e1007111.	4.7	46
76	Hepatitis C Virus P7â€"A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy. Viruses, 2010, 2, 2078-2095.	3.3	44
77	Subcellular Localization and Function of an Epitope-Tagged p7 Viroporin in Hepatitis C Virus-Producing Cells. Journal of Virology, 2013, 87, 1664-1678.	3.4	42
78	Role of Hypervariable Region 1 for the Interplay of Hepatitis C Virus with Entry Factors and Lipoproteins. Journal of Virology, 2014, 88, 12644-12655.	3.4	42
79	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses, 2015, 7, 3995-4046.	3.3	42
80	Immune protection against reinfection with nonprimate hepacivirus. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2430-E2439.	7.1	42
81	Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Research, 2011, 89, 136-148.	4.1	41
82	HCV Pit Stop at the Lipid Droplet: Refuel Lipids and Put on a Lipoprotein Coat before Exit. Cells, 2019, 8, 233.	4.1	41
83	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. Journal of Virology, 2011, 85, 7613-7621.	3.4	40
84	Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology, 2014, 59, 78-88.	7.3	40
85	Hepatitis C Virus Entry: Protein Interactions and Fusion Determinants Governing Productive Hepatocyte Invasion. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036830.	6.2	40
86	Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO Journal, 2000, 19, 3436-3445.	7.8	38
87	Interferon Î±â€"Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. Journal of Infectious Diseases, 2012, 205, 1351-1362.	4.0	38
88	Virucidal activity of 2 alcohol-based formulations proposed as hand rubs byÂthe World Health Organization. American Journal of Infection Control, 2010, 38, 66-68.	2.3	34
89	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. Gastroenterology, 2012, 143, 439-447.e1.	1.3	30
90	Hepatitis C Virus Replication in Mouse Cells Is Restricted by IFN-Dependent and -Independent Mechanisms. Gastroenterology, 2013, 145, 1414-1423.e1.	1.3	30

#	Article	IF	Citations
91	Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Research, 2020, 177, 104774.	4.1	30
92	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS ONE, 2015, 10, e0134529.	2.5	30
93	Tissue culture and animal models for hepatitis C virus. Clinics in Liver Disease, 2003, 7, 23-43.	2.1	29
94	Final entry key for hepatitis C. Nature, 2009, 457, 797-798.	27.8	28
95	Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. Journal of Hepatology, 2015, 63, 813-821.	3.7	28
96	Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Research, 2017, 147, 19-28.	4.1	28
97	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. Journal of Virology, 2016, 90, 10670-10681.	3.4	27
98	ABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus Production. PLoS Pathogens, 2016, 12, e1005568.	4.7	26
99	The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly. PLoS Pathogens, 2020, 16, e1008554.	4.7	25
100	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. Journal of Viral Hepatitis, 2011, 18, 562-570.	2.0	24
101	Decoding protein networks during virus entry by quantitative proteomics. Virus Research, 2016, 218, 25-39.	2.2	24
102	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. PLoS Pathogens, 2011, 7, e1002029.	4.7	23
103	Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons. Journal of Virology, 2015, 89, 3833-3845.	3.4	23
104	Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	10.3	23
105	Bile Acids Specifically Increase Hepatitis C Virus RNA-Replication. PLoS ONE, 2012, 7, e36029.	2.5	23
106	Identification of a Human Respiratory Syncytial Virus Cell Entry Inhibitor by Using a Novel Lentiviral Pseudotype System. Journal of Virology, 2016, 90, 3065-3073.	3.4	22
107	Characterization of the Prototype Foamy Virus Envelope Glycoprotein Receptor-Binding Domain. Journal of Virology, 2006, 80, 8158-8167.	3.4	21
108	Escape from a Dominant HLA-B*15-Restricted CD8 ⁺ T Cell Response against Hepatitis C Virus Requires Compensatory Mutations outside the Epitope. Journal of Virology, 2012, 86, 991-1000.	3.4	21

#	Article	IF	Citations
109	Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice. Gut, 2016, 65, 2029-2034.	12.1	21
110	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. Journal of Virology, 2017, 91, .	3.4	21
111	Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 2022, 55, 341-354.e7.	14.3	21
112	Determinants of foamy virus envelope glycoprotein mediated resistance to superinfection. Virology, 2003, 314, 243-252.	2.4	20
113	High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants. Journal of Biological Chemistry, 2012, 287, 39224-39232.	3.4	20
114	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
115	Specific Binding of Recombinant Foamy Virus Envelope Protein to Host Cells Correlates with Susceptibility to Infection. Virology, 1999, 255, 228-236.	2.4	19
116	Total Synthesis of a Noricumazoleâ€…A Library and Evaluation of HCV Inhibition. Chemistry - A European Journal, 2012, 18, 9083-9090.	3.3	19
117	Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases. Journal of Virology, 2017, 91, .	3.4	19
118	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. Journal of General Virology, 2015, 96, 2636-2642.	2.9	19
119	Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment. Journal of Virology, 2013, 87, 13297-13306.	3.4	18
120	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut, 2020, 69, 1659-1666.	12.1	18
121	Application of the trak-Câ„¢ HCV core assay for monitoring antiviral activity in HCV replication systems. Journal of Virological Methods, 2004, 118, 23-31.	2.1	17
122	Thermostability of seven hepatitis C virus genotypes in vitro and in vivo. Journal of Viral Hepatitis, 2013, 20, 478-485.	2.0	17
123	Characterization of the inhibition of hepatitis C virus entry byIn vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology, 2013, 57, 1716-1724.	7.3	16
124	Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8 ⁺ T Cell Response by Selection of Altered Epitope Processing. Journal of Virology, 2016, 90, 33-42.	3.4	16
125	Specific Acquisition of Functional CD59 but Not CD46 or CD55 by Hepatitis C Virus. PLoS ONE, 2012, 7, e45770.	2.5	15
126	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Journal of Hepatology, 2019, 70, 1082-1092.	3.7	15

#	Article	IF	Citations
127	Regulation of hepatitis C virus replication by microRNAs. Journal of Hepatology, 2009, 50, 441-444.	3.7	14
128	Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. MBio, 2016, 7, .	4.1	13
129	CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells. Viruses, 2018, 10, 207.	3.3	13
130	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
131	Controlled Functional Zonation of Hepatocytes In Vitro by Engineering of Wnt Signaling. ACS Synthetic Biology, 2020, 9, 1638-1649.	3.8	13
132	Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements. Journal of Virology, 2021, 95, .	3.4	13
133	Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region. Antiviral Research, 2014, 110, 52-59.	4.1	12
134	Prolonged Survival of Hepatitis C Virus in the Anesthetic Propofol. Clinical Infectious Diseases, 2011, 53, 963-964.	5.8	11
135	Physicochemical Properties Govern the Activity of Potent Antiviral Flavones. ACS Omega, 2019, 4, 4871-4887.	3.5	11
136	Characterization of RNA Sensing Pathways in Hepatoma Cell Lines and Primary Human Hepatocytes. Cells, 2021, 10, 3019.	4.1	10
137	Sandacrabins â€“ Structurally Unique Antiviral RNA Polymerase Inhibitors from a Rare Myxobacterium**. Chemistry - A European Journal, 2022, 28, e202104484.	3.3	10
138	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. Virus Evolution, 2022, 8, veac007.	4.9	10
139	Efficient Virus Assembly, but Not Infectivity, Determines the Magnitude of Hepatitis C Virus-Induced Interferon Alpha Responses of Plasmacytoid Dendritic Cells. Journal of Virology, 2015, 89, 3200-3208.	3.4	9
140	Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. Alimentary Pharmacology and Therapeutics, 2015, 41, 532-543.	3.7	9
141	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
142	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. PLoS ONE, 2011, 6, e24142.	2.5	9
143	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2010, 4, 63-79.	3.0	8
144	Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. PLoS ONE, 2014, 9, e102235.	2.5	8

#	Article	IF	Citations
145	Full-Length Infectious HCV Chimeras. Methods in Molecular Biology, 2009, 510, 347-359.	0.9	8
146	Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C. Current Hepatitis Reports, 2013, 12, 200-213.	0.3	7
147	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. Hepatology, 2014, 60, 508-520.	7.3	7
148	Hepatitis C virus plays hide and seek with neutralizing antibodies. Hepatology, 2016, 64, 1840-1842.	7.3	7
149	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. Hepatology, 2016, 64, 2274-2276.	7.3	7
150	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. Viruses, 2019, 11, 275.	3.3	7
151	OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease. PLoS ONE, 2020, 15, e0236447.	2.5	7
152	Replication-Competent Hybrids between Murine Leukemia Virus and Foamy Virus. Journal of Virology, 2003, 77, 7677-7681.	3.4	6
153	The Suppressive Effect That Myriocin Has on Hepatitis C Virus RNA Replication Is Independent of Inhibition of Serine Palmitoyl Transferase. Journal of Infectious Diseases, 2008, 198, 1091-1093.	4.0	6
154	Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Medical Microbiology and Immunology, 2020, 209, 499-514.	4.8	6
155	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, 139, 129-137.	4.1	5
156	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells, 2019, 8, 610.	4.1	5
157	Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. Journal of Virology, 2016, 90, 5075-5089.	3.4	4
158	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters, 2017, 6, 935-940.	4.8	4
159	Hepatitis C Virus Stimulates Murine CD8Î±-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathogens, 2016, 12, e1005736.	4.7	4
160	The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. Journal of Virology, 2022, 96, e0199521.	3.4	4
161	Stability and transmission of hepatitis CÂvirus in different anesthetic agents. American Journal of Infection Control, 2013, 41, 942-943.	2.3	3
162	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. Antiviral Research, 2012, 96, 51-58.	4.1	2

#	Article	IF	Citations
163	Hepatitis C virus NS5B polymerase primes innate immune signaling. Hepatology, 2013, 57, 1275-1277.	7.3	2
164	In sero veritas: what serum markers teach us about HCV infection of primary human hepatocytes. Gut, 2014, 63, 1375-1377.	12.1	2
165	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. Journal of Virology, 2014, 88, 667-678.	3.4	2
166	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. Cancer Cell, 2009, 16, 447.	16.8	1
167	Cell culture-derived HCV cannot infect synovial fibroblasts. Scientific Reports, 2015, 5, 18043.	3.3	1
168	Magnesium Complexes of Ladanein: A Beneficial Strategy for Stabilizing Polyphenolic Antivirals. European Journal of Inorganic Chemistry, 2021, 2021, 2764-2772.	2.0	1
169	Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors. Journal of Visualized Experiments, 2012, , e4029.	0.3	0
170	A circuit of paracrine signals between liver sinusoid endothelial cells and hepatocytes regulates hepatitis C virus replication. Hepatology, 2014, 59, 363-365.	7.3	0
171	Hepatitis C Virus Replication in Cell Culture. , 2004, , 108-122.		0